Sera Prognostics, Inc.

Sera Prognostics, Inc. (SERA) priced its initial public offering on Jul 16, 2021 at $16.00 per share, within its $15.00–$17.00 range, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $488.1M. Citigroup was lead-left underwriter, joined by TD Cowen and William Blair. Mintz advised the company and Goodwin Procter advised the underwriters.

Sera Prognostics, Inc. is a women's health diagnostic company that uses a proprietary proteomics and bioinformatics platform to discover and commercialize biomarker tests. Its initial focus is improving pregnancy outcomes, giving physicians and patients data on maternal and neonatal health.

Status

IPO

Ticker

SERA

Exchange

Nasdaq Global Market

Priced

Jul 16, 2021

IPO price

$16.00

Price range

$15.00–$17.00

Market cap at IPO price

$488.1M

First filed

Jun 11, 2021

Underwriters

Citigroup, TD Cowen and William Blair

Company counsel

Mintz

Underwriters' counsel

Goodwin Procter

Sector

Healthcare

Country / state

UT

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.